1964 related articles for article (PubMed ID: 7937717)
1. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
4. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
5. [Expression of P53 protein in cutaneous melanoma].
Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M
Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650
[TBL] [Abstract][Full Text] [Related]
6. Expression of mutant p53 in melanoma.
Stretch JR; Gatter KC; Ralfkiaer E; Lane DP; Harris AL
Cancer Res; 1991 Nov; 51(21):5976-9. PubMed ID: 1933861
[TBL] [Abstract][Full Text] [Related]
7. p53 Protein expression in nevi and melanomas.
Cristofolini M; Boi S; Girlando S; Zumiani G; Cristofolini P; Dalla Palma P; Doglioni C; Barbareschi M
Arch Dermatol; 1993 Jun; 129(6):739-43. PubMed ID: 8507076
[TBL] [Abstract][Full Text] [Related]
8. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.
Richmond-Sinclair NM; Lee E; Cummings MC; Williamson R; Muller K; Green AC; Hayward NK; Whiteman DC
Melanoma Res; 2008 Oct; 18(5):336-45. PubMed ID: 18781132
[TBL] [Abstract][Full Text] [Related]
9. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma.
Kawasaki K; Kawakami T; Watabe H; Itoh F; Mizoguchi M; Soma Y
Br J Dermatol; 2007 Apr; 156(4):613-9. PubMed ID: 17493064
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of XIAP in melanoma.
Emanuel PO; Phelps RG; Mudgil A; Shafir M; Burstein DE
J Cutan Pathol; 2008 Mar; 35(3):292-7. PubMed ID: 18251743
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
[TBL] [Abstract][Full Text] [Related]
15. Malignant melanoma of the oesophagus: clinicopathological features, lack of p53 expression and steroid receptors and a review of the literature.
Lam KY; Law S; Wong J
Eur J Surg Oncol; 1999 Apr; 25(2):168-72. PubMed ID: 10218460
[TBL] [Abstract][Full Text] [Related]
16. Analysis of p53 in human cutaneous melanoma cell lines.
Montano X; Shamsher M; Whitehead P; Dawson K; Newton J
Oncogene; 1994 May; 9(5):1455-9. PubMed ID: 8152807
[TBL] [Abstract][Full Text] [Related]
17. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions.
Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J
Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
19. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study.
Argenyi ZB; Cain C; Bromley C; Nguyen AV; Abraham AA; Kerschmann R; LeBoit PE
Am J Dermatopathol; 1994 Jun; 16(3):233-40. PubMed ID: 7943629
[TBL] [Abstract][Full Text] [Related]
20. Expression of p53 protein in cutaneous melanoma.
Akslen LA; Mørkve O
Int J Cancer; 1992 Aug; 52(1):13-6. PubMed ID: 1500218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]